Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · Real-Time Price · USD
1.200
+0.020 (1.69%)
At close: Jun 24, 2025, 4:00 PM
1.190
-0.010 (-0.83%)
After-hours: Jun 24, 2025, 6:06 PM EDT
1.69%
Market Cap 23.00M
Revenue (ttm) n/a
Net Income (ttm) -13.40M
Shares Out 19.16M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 86,813
Open 1.180
Previous Close 1.180
Day's Range 1.170 - 1.239
52-Week Range 0.870 - 2.550
Beta 0.62
Analysts Strong Buy
Price Target 8.50 (+608.33%)
Earnings Date Aug 20, 2025

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 20
Stock Exchange NASDAQ
Ticker Symbol CMMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 608.33% from the latest price.

Price Target
$8.5
(608.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strate...

13 days ago - GlobeNewsWire

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands Prote...

21 days ago - GlobeNewsWire

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M oderate/ A dvanced D isease R esulted in C ontinued I mprovements across K ey B iomarkers of Li ver I n...

5 weeks ago - GlobeNewsWire

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and...

7 weeks ago - GlobeNewsWire

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.

2 months ago - GlobeNewsWire

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory disea...

2 months ago - GlobeNewsWire

Chemomab Announces New Medical and Clinical Appointments

David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Ove...

2 months ago - GlobeNewsWire

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab Therapeutics Ltd. CMMB on Thursday released results from the Open Label Extension (OLE) portion of the Phase 2 Spring trial assessing nebokitug for primary sclerosing cholangitis (PSC).

3 months ago - Benzinga

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.

3 months ago - GlobeNewsWire

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, ...

3 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory approval

4 months ago - GlobeNewsWire

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC.

4 months ago - GlobeNewsWire

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts”— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- ...

7 months ago - GlobeNewsWire

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Oral presentation at AASLD highlights broad clinical activity of Chemomab's CM-101 across multiple biomarkers and its disease-modifying potential in PSC

7 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.

10 months ago - GlobeNewsWire

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics f...

11 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026

11 months ago - GlobeNewsWire

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

11 months ago - GlobeNewsWire

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.

11 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints

11 months ago - GlobeNewsWire

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —Ne...

1 year ago - GlobeNewsWire

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

1 year ago - GlobeNewsWire

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrol...

1 year ago - GlobeNewsWire

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

1 year ago - GlobeNewsWire

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

1 year ago - GlobeNewsWire